Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Sumitomo Dainippon Pharma Co Ltd patents


Recent patent applications related to Sumitomo Dainippon Pharma Co Ltd. Sumitomo Dainippon Pharma Co Ltd is listed as an Agent/Assignee. Note: Sumitomo Dainippon Pharma Co Ltd may have other listings under different names/spellings. We're not affiliated with Sumitomo Dainippon Pharma Co Ltd, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Sumitomo Dainippon Pharma Co Ltd-related inventors


Transplantation adjuvant in cell therapy using neural progenitor cells

The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient.... Sumitomo Dainippon Pharma Co Ltd

Method for discriminating symptom of hepatic disease

Provided is a noninvasive method for determining the presence of a symptom of a hepatic disease such as nonalcoholic fatty liver disease with a higher diagnostic accuracy. A method for discriminate between nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), the method comprising: (1) a step of measuring the quantities... Sumitomo Dainippon Pharma Co Ltd

Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder

Dosage regimens for at least one compound chosen from lurasidone and pharmaceutically acceptable salts, solvates, clathrates, and stereoisomers thereof are disclosed as are kits and methods for treatment and/or prevention of at least one CNS disorder such as, for example, mixed depression and bipolar disorder, and management of at least... Sumitomo Dainippon Pharma Co Ltd

Agent for treatment of schizophrenia

The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily... Sumitomo Dainippon Pharma Co Ltd

Bicyclic imidazolo derivative

Disclosed are compounds, having the following structure, useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions comprising the compounds, and methods of using the same.... Sumitomo Dainippon Pharma Co Ltd

Tumor antigen peptide

The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active... Sumitomo Dainippon Pharma Co Ltd

Production nerve tissue

(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.... Sumitomo Dainippon Pharma Co Ltd

Production retinal tissue

(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.... Sumitomo Dainippon Pharma Co Ltd

Ophthalmic suspension formulation

The present invention relates to a stable ophthalmic suspension formulation comprising (R)-(−)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone, which is useful for treating a disease in posterior eye segment and the like, avoiding side-effects due to systemic exposure.... Sumitomo Dainippon Pharma Co Ltd

Tricyclic derivative

Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.... Sumitomo Dainippon Pharma Co Ltd

Pyrazole compound

or a pharmaceutically acceptable salt thereof wherein R1, R2 , R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3... Sumitomo Dainippon Pharma Co Ltd

Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva

The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.... Sumitomo Dainippon Pharma Co Ltd

Medicament-containing hollow particle

The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a... Sumitomo Dainippon Pharma Co Ltd

1,4-disubstituted imidazole derivative

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1′) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is... Sumitomo Dainippon Pharma Co Ltd

Novel benzimidazole compound and medical use thereof

or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10... Sumitomo Dainippon Pharma Co Ltd

Compositions of obeticholic acid and methods of use

The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.... Sumitomo Dainippon Pharma Co Ltd

Condensed 5-oxazolidinone derivative

Provided are condensed 5-oxazolidinone derivatives and pharmaceutically permissible salts thereof, which have excellent anticoagulant effects, are well absorbed orally, and are useful as therapeutic drugs for thrombosis, etc. Compounds represented by formula (1) and pharmaceutically permissible salts thereof. [In the formula, L represents a C1-C4 alkylene group that may be... Sumitomo Dainippon Pharma Co Ltd








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Sumitomo Dainippon Pharma Co Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sumitomo Dainippon Pharma Co Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###